Another Major Drug Approval for Regeneron
Congratulations to BCW member Regeneron on the approval of an important new drug to help patients with rheumatoid arthritis. The U.S. Food and Drug Administration has approved the human antibody drug sarilumab, developed by Regeneron Pharmaceuticals Inc. in Westchester and its French pharmaceutical partner Sanofi and trademarked as Kevzara, to treat adult patients with moderately to severely active rheumatoid arthritis.
The FDA approval came less than two months after the federal agency approved Regeneron’s and Sanofi’s human antibody dupilumab, marketed as Dupixent, as the first biologic medicine used to treat the debilitating itching and widespread rashes afflicting adults with moderate to severe cases of atopic dermatitis.
Similar News Items
BCW Member Northwell Health is going to be the lead sponsor of the professional soccer team that is going to make its home at Mount Vernon’s Memorial Field, according to an announcement from BCW Member Westchester Soccer Club (WSC), a new USL League One franchise. Northwell has committed to the sponsorship for the club’s inaugural […]
BCW Westchester Innovation Network participant Laronix held a showcase Wednesday to demonstrate its MIRA Voice device that uses artificial intelligence to help people with spinal cord injuries, cerebral palsy and other conditions regain the ability to speak clearly. The event at Serendipity Labs in White Plains welcomed medical professionals and others curious about MIRA Voice […]
Congratulations to BCW Member Westchester Medical Center Health Network (WMCHealth) on the groundbreaking Wednesday to commemorate the start of construction of the Critical Care Tower at Westchester Medical Center, a $220 million project that will span 162,000 square feet and rise five stories when complete. Located adjacent to Westchester Medical Center’s Main Tower, the Critical […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.